ArticleScientific reports2025
Gene expression and agent-based modeling improve precision prognosis in breast cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Data-intensive immune network modelling for One Health.Briefings in bioinformatics · 2026Review
- Development of a prognostic prediction model incorporatingJournal of gastrointestinal oncology · 2026Article
- Agentic AI and the rise of in silico team science in biomedical research.Nature biotechnology · 2026Review
- AI-based methods for the assessment of DNA damage and repair mechanisms.Frontiers in systems biology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer survival is hard to predict because of the complex ways genes and cells interact. This study offers a new method to improve these predictions by combining gene expression profiling (GEP) with agent-based modeling (ABM). First, GEP will pinpoint genes that are important in breast cancer development. Then, a mathematical model will be built to show how these genes influence cell behavior. This data will be used in ABM to simulate tumor growth and treatment response. The ABM allows us to virtually test different treatments and see how they might affect patient survival. Finally, the model's accuracy will be checked against real patient data and compared to other models. By combining the strengths of GEP and ABM, this research could significantly improve breast cancer survival prediction. ABM's ability to analyze interactions mathematically could pave the way for more personalized and effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.